Printer Friendly

Antibe Therapeutics Launches Bone Graft Substitute for Oral, Maxillofacial Surgery.

M2 PHARMA-April 19, 2016-Antibe Therapeutics Launches Bone Graft Substitute for Oral, Maxillofacial Surgery

(C)2016 M2 COMMUNICATIONS

- Canadian pain and inflammation therapies company Antibe Therapeutics Inc.'s (TSX Venture: ATE) (OTCQX: ATBPF) Citagenix Inc. tissue regenerative products subsidiary has launched PentOS OI Putty, the first product of a new family of bone graft substitutes that have a proven ability to form bone, Antibe said.

According to the company, PentOS OI Putty will be available to oral and maxillofacial surgery customers and will be joined by three additional PentOS OI products that are expected to launch in the coming months: PentOS OI Flex, PentOS OI Sponge and PentOS OI Fill.

PentOS OI Putty is a demineralised bone matrix made from 100% human bone and does not contain any extrinsic carriers.

All of the PentOS OI grafts are verified for osteo-inductivity prior to distribution to ensure that each graft facilitates bone formation.

Independent in vivo testing (post-sterilization) demonstrates all five elements of bone formation are present in our PentOS OI grafts: chondrocytes, osteocytes, bone marrow cells, cartilage, and new bone. In vitro tests of PentOS OI demonstrate levels of bone morphogenetic protein-2 up to 19-times the control levels.

PentOS OI Putty will be offered in the Canadian market through our direct sales force and globally via our network of distribution partners.

Antibe develops medicines for pain and inflammation. The company's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine.

The company's lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation.

ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.

Antibe's subsidiary, Citagenix Inc. (Citagenix), is in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces.

Since its inception in 1997, Citagenix has become the largest source of knowledge and experience in the Canadian medical device industry.

Citagenix Inc. is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 19, 2016
Words:369
Previous Article:St. Jude Medical Launches First US Implants of MultiPoint Pacing Technology.
Next Article:ChromaDex Corp unveils NIAGEN & Collagen dietary supplement in the health market.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters